文献速递心脑血管急症重症综合管理与镇静镇痛

伴与不伴心脏骤停的STEMI患者血栓与出血平衡:一项观察性研究

The balance of thrombosis and hemorrhage in STEMI patients with or without associated cardiac arrest: An observational study.
PubMed 文献 · Resuscitation · 2019-11-01
一句话结论伴院外心脏骤停的STEMI患者支架血栓和大出血发生率均显著高于不伴心脏骤停者,抗凝治疗和糖蛋白IIb/IIIa抑制剂是大出血的独立预测因素。

本研究为单中心回顾性观察性研究,纳入2012年1月至2017年12月期间接受支架植入的STEMI患者,比较伴与不伴院外心脏骤停(OHCA)患者的基线特征、治疗及出血和血栓事件。结果显示,OHCA组明确支架血栓(2.6% vs. 7.5%,p=0.004)和大出血(3.3% vs. 19.2%,p<0.001)发生率均显著高于非OHCA组。在OHCA患者中,抗凝治疗(HR=3.11)和糖蛋白IIb/IIIa抑制剂使用(HR=4.16)是大出血的独立预测因素;年龄(HR=1.05)和支架血栓(HR=5.62)是死亡的独立预测因素,而新型抗P2Y12治疗显示保护作用(HR=0.20)。作者认为该人群需前瞻性研究以更好评估血栓与出血平衡。

要点

  • 伴OHCA的STEMI患者支架植入后明确支架血栓发生率显著高于不伴OHCA者(2.6% vs. 7.5%,p=0.004)。
  • 伴OHCA的STEMI患者大出血发生率显著高于不伴OHCA者(3.3% vs. 19.2%,p<0.001)。
  • 在OHCA患者中,抗凝治疗(HR=3.11,95%CI 1.22-7.98)和糖蛋白IIb/IIIa抑制剂(HR=4.16,95%CI 1.61-10.79)是大出血的独立预测因素。
  • 在OHCA患者中,年龄(HR=1.05,95%CI 1.02-1.09)和支架血栓(HR=5.62,95%CI 1.61-19.65)是死亡的独立预测因素,新型抗P2Y12治疗具保护作用(HR=0.20,95%CI 0.08-0.46)。

适用人群与场景

  • 纳入2012年1月至2017年12月期间在一家三级大学医院(作为大型城市区域的心脏骤停中心)连续接受支架植入治疗的STEMI患者,包括伴或不伴OHCA者。

研究设计与关键结果

  • 研究类型为单中心回顾性观察性研究;共纳入549例不伴OHCA的STEMI患者和146例伴OHCA的STEMI患者。
  • 伴OHCA患者明确支架血栓发生率显著高于不伴OHCA者(2.6% vs. 7.5%,p=0.004)。
  • 伴OHCA患者大出血发生率显著高于不伴OHCA者(3.3% vs. 19.2%,p<0.001)。
  • 在OHCA患者中,大出血的独立预测因素为抗凝治疗(HR=3.11,95%CI 1.22-7.98,p=0.02)和糖蛋白IIb/IIIa抑制剂使用(HR=4.16,95%CI 1.61-10.79,p=0.003)。
  • 在OHCA患者中,死亡的独立预测因素为年龄(HR=1.05,95%CI 1.02-1.09,p=0.004)和支架血栓(HR=5.62,95%CI 1.61-19.65,p=0.007),新型抗P2Y12治疗显示保护作用(HR=0.20,95%CI 0.08-0.46,p<0.001)。

证据类型、等级与局限

  • 证据类型:单中心回顾性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 伴OHCA的STEMI患者支架植入后血栓和出血风险均高于不伴OHCA者,提示需关注该人群的抗栓平衡。
  • 作者认为,在该亚组患者中需前瞻性研究以更好地评估血栓与出血的平衡。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Data is scarce on hemorrhagic and thrombotic complications in patients with ST-elevation myocardial infarction (STEMI) associated with out-of-hospital cardiac arrest (OHCA).

METHODS: This is a monocentric, retrospective study conducted from January 2012 to December 2017 in a tertiary university hospital, which serves as a cardiac arrest center for a large urban area. Over the study period, all consecutive patients who were treated with stent implantation for STEMI with or without OHCA were included. Baseline characteristics, treatments, hemorrhagic and thrombotic events were compared between STEMI patients with and without OHCA. Univariate and multivariate analysis were performed in order to identify predictors of 30-day mortality, occurrence of major bleeding (MB), and early stent thrombosis (ST).

RESULTS: A total of 549 patients treated for STEMI without OHCA and 146 patients for STEMI with OHCA were included. The incidence of definite ST and MB after coronary angioplasty was significantly higher in patients with OHCA (2.6% vs. 7.5%, p = 0.004 and 3.3% vs. 19.2%, p < 0.001, respectively). Independent predictors of MB in OHCA patients were anticoagulation therapy (HR = 3.11, 95%CI [1.22-7.98], p = 0.02) and the use of glycoprotein IIb/IIIa inhibitors (HR = 4.16, 95%CI [1.61-10.79], p = 0.003). Independent predictors of mortality in OHCA patients were age (HR = 1.05, 95%CI [1.02-1.09], p = 0.004) and ST (HR = 5.62, 95%CI [1.61-19.65], p = 0.007, with a protective effect of new anti-P2Y12 treatments (HR = 0.20, 95%CI [0.08-0.46], p < 0.001).

CONCLUSION: Patients treated for STEMI associated with OHCA are at higher-risk of ST and MB than those who did not experience cardiac arrest. In this subset of patients, prospective studies are needed to better evaluate the balance of thrombosis and hemorrhage.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Picard F, Llitjos JF, Diefenbronn M, et al. The balance of thrombosis and hemorrhage in STEMI patients with or without associated cardiac arrest: An observational study. Resuscitation. 2019. PMID: 31682901. doi:10.1016/j.resuscitation.2019.10.022

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。